Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Metabolon is raising $48,016,399.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Rohan Hastie played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Metabolon

Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to reveal biological pathways. We make connections where other ‘omics cannot, and provide the definitive representation of the phenotype. Our work measures inputs from internal and external factors such as health, disease, nutrition, microbiome, medication, pollution, and more, to drive success in answering scientific questions about health and disease. Every day, we accelerate research that leads to successes in biopharma, population health, consumer products, agriculture, wellness, and academic and government research sectors. This work has enabled modern science to gain a foothold in our understanding of complex disease, ultimately leading to the creation of new treatments that impact individuals and communities globally. Our scalable, customizable metabolomics solutions provide support across the research continuum from discovery through clinical trials, to in-market life cycle management.

To learn more about Metabolon, visit http://www.metabolon.com/

Contact:
Rohan Hastie, Chief Executive Officer
919-572-1711
rhastie@metabolon.com
https://www.linkedin.com/in/rohan-ro-hastie-6b57764/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved